# Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

> **NCT03246009** · PHASE1 · COMPLETED · sponsor: **Tianjin SinoBiotech Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Chemotherapy-induced Neutropenia
- Cancer, Breast

## Interventions

- **DRUG:** rHSA/GCSF
- **DRUG:** rHSA/GCSF
- **DRUG:** rHSA/GCSF
- **DRUG:** rHSA/GCSF
- **DRUG:** rHSA/GCSF
- **DRUG:** rHSA/GCSF

## Key facts

- **NCT ID:** NCT03246009
- **Lead sponsor:** Tianjin SinoBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-21
- **Primary completion:** 2017-04-10
- **Final completion:** 2017-04-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246009, "Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03246009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*